Diagnosis of complement alternative pathway disorders

Andrea Angioi, Fernando Custodio Fervenza, Sanjeev M Sethi, Yuzhou Zhang, Richard J. Smith, David Murray, Jens Van Praet, Antonello Pani, An S. De Vriese

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Kidney diseases resulting from abnormal control of the complement alternative pathway include atypical hemolytic uremic syndrome, C3 glomerulonephritis, and dense-deposit disease, as well as atypical postinfectious glomerulonephritis. Although clinically diverse, they all result from loss of surface or fluid-phase complement control, caused by acquired or genetic defects in the complement alternative pathway. As such, the diagnostic approach is similar and includes a comprehensive biochemical, genetic, and pathologic analysis of the complement pathway. The biochemical test battery includes functional activity measurements of the entire complement pathway, functional and quantitative analysis of individual components and regulators, and quantification of activation products. In patients with a thrombotic microangiopathy, ADAMTS-13 activity should be determined to exclude a thrombotic thrombocytopenic purpura. The spectrum of genes currently known to be involved in the pathogenesis of alternative pathway disorders is rapidly expanding. Pathologic analysis of a kidney biopsy specimen is sophisticated with ad hoc immunofluorescence studies and laser microdissection with mass spectrometry. The identification of the underlying defect in the alternative pathway based on this comprehensive analysis will allow treatment to be directed to the site of dysregulation.

Original languageEnglish (US)
Pages (from-to)278-288
Number of pages11
JournalKidney International
Volume89
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Alternative Complement Pathway
Glomerulonephritis
Thrombotic Microangiopathies
Membranoproliferative Glomerulonephritis
Thrombotic Thrombocytopenic Purpura
Microdissection
Kidney Diseases
Fluorescent Antibody Technique
Molecular Biology
Mass Spectrometry
Lasers
Kidney
Biopsy
Genes
Therapeutics
Atypical Hemolytic Uremic Syndrome

Keywords

  • alternative pathway
  • atypical hemolytic uremic syndrome
  • C3 glomerulonephritis
  • C3 glomerulopathy
  • classical pathway
  • complement
  • dense-deposit disease
  • glomerulonephritis

ASJC Scopus subject areas

  • Nephrology

Cite this

Angioi, A., Fervenza, F. C., Sethi, S. M., Zhang, Y., Smith, R. J., Murray, D., ... De Vriese, A. S. (2016). Diagnosis of complement alternative pathway disorders. Kidney International, 89(2), 278-288. https://doi.org/10.1016/j.kint.2015.12.003

Diagnosis of complement alternative pathway disorders. / Angioi, Andrea; Fervenza, Fernando Custodio; Sethi, Sanjeev M; Zhang, Yuzhou; Smith, Richard J.; Murray, David; Van Praet, Jens; Pani, Antonello; De Vriese, An S.

In: Kidney International, Vol. 89, No. 2, 01.02.2016, p. 278-288.

Research output: Contribution to journalArticle

Angioi, A, Fervenza, FC, Sethi, SM, Zhang, Y, Smith, RJ, Murray, D, Van Praet, J, Pani, A & De Vriese, AS 2016, 'Diagnosis of complement alternative pathway disorders', Kidney International, vol. 89, no. 2, pp. 278-288. https://doi.org/10.1016/j.kint.2015.12.003
Angioi, Andrea ; Fervenza, Fernando Custodio ; Sethi, Sanjeev M ; Zhang, Yuzhou ; Smith, Richard J. ; Murray, David ; Van Praet, Jens ; Pani, Antonello ; De Vriese, An S. / Diagnosis of complement alternative pathway disorders. In: Kidney International. 2016 ; Vol. 89, No. 2. pp. 278-288.
@article{c9f971509b51497ebbba75955ec90b15,
title = "Diagnosis of complement alternative pathway disorders",
abstract = "Kidney diseases resulting from abnormal control of the complement alternative pathway include atypical hemolytic uremic syndrome, C3 glomerulonephritis, and dense-deposit disease, as well as atypical postinfectious glomerulonephritis. Although clinically diverse, they all result from loss of surface or fluid-phase complement control, caused by acquired or genetic defects in the complement alternative pathway. As such, the diagnostic approach is similar and includes a comprehensive biochemical, genetic, and pathologic analysis of the complement pathway. The biochemical test battery includes functional activity measurements of the entire complement pathway, functional and quantitative analysis of individual components and regulators, and quantification of activation products. In patients with a thrombotic microangiopathy, ADAMTS-13 activity should be determined to exclude a thrombotic thrombocytopenic purpura. The spectrum of genes currently known to be involved in the pathogenesis of alternative pathway disorders is rapidly expanding. Pathologic analysis of a kidney biopsy specimen is sophisticated with ad hoc immunofluorescence studies and laser microdissection with mass spectrometry. The identification of the underlying defect in the alternative pathway based on this comprehensive analysis will allow treatment to be directed to the site of dysregulation.",
keywords = "alternative pathway, atypical hemolytic uremic syndrome, C3 glomerulonephritis, C3 glomerulopathy, classical pathway, complement, dense-deposit disease, glomerulonephritis",
author = "Andrea Angioi and Fervenza, {Fernando Custodio} and Sethi, {Sanjeev M} and Yuzhou Zhang and Smith, {Richard J.} and David Murray and {Van Praet}, Jens and Antonello Pani and {De Vriese}, {An S.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.kint.2015.12.003",
language = "English (US)",
volume = "89",
pages = "278--288",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Diagnosis of complement alternative pathway disorders

AU - Angioi, Andrea

AU - Fervenza, Fernando Custodio

AU - Sethi, Sanjeev M

AU - Zhang, Yuzhou

AU - Smith, Richard J.

AU - Murray, David

AU - Van Praet, Jens

AU - Pani, Antonello

AU - De Vriese, An S.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Kidney diseases resulting from abnormal control of the complement alternative pathway include atypical hemolytic uremic syndrome, C3 glomerulonephritis, and dense-deposit disease, as well as atypical postinfectious glomerulonephritis. Although clinically diverse, they all result from loss of surface or fluid-phase complement control, caused by acquired or genetic defects in the complement alternative pathway. As such, the diagnostic approach is similar and includes a comprehensive biochemical, genetic, and pathologic analysis of the complement pathway. The biochemical test battery includes functional activity measurements of the entire complement pathway, functional and quantitative analysis of individual components and regulators, and quantification of activation products. In patients with a thrombotic microangiopathy, ADAMTS-13 activity should be determined to exclude a thrombotic thrombocytopenic purpura. The spectrum of genes currently known to be involved in the pathogenesis of alternative pathway disorders is rapidly expanding. Pathologic analysis of a kidney biopsy specimen is sophisticated with ad hoc immunofluorescence studies and laser microdissection with mass spectrometry. The identification of the underlying defect in the alternative pathway based on this comprehensive analysis will allow treatment to be directed to the site of dysregulation.

AB - Kidney diseases resulting from abnormal control of the complement alternative pathway include atypical hemolytic uremic syndrome, C3 glomerulonephritis, and dense-deposit disease, as well as atypical postinfectious glomerulonephritis. Although clinically diverse, they all result from loss of surface or fluid-phase complement control, caused by acquired or genetic defects in the complement alternative pathway. As such, the diagnostic approach is similar and includes a comprehensive biochemical, genetic, and pathologic analysis of the complement pathway. The biochemical test battery includes functional activity measurements of the entire complement pathway, functional and quantitative analysis of individual components and regulators, and quantification of activation products. In patients with a thrombotic microangiopathy, ADAMTS-13 activity should be determined to exclude a thrombotic thrombocytopenic purpura. The spectrum of genes currently known to be involved in the pathogenesis of alternative pathway disorders is rapidly expanding. Pathologic analysis of a kidney biopsy specimen is sophisticated with ad hoc immunofluorescence studies and laser microdissection with mass spectrometry. The identification of the underlying defect in the alternative pathway based on this comprehensive analysis will allow treatment to be directed to the site of dysregulation.

KW - alternative pathway

KW - atypical hemolytic uremic syndrome

KW - C3 glomerulonephritis

KW - C3 glomerulopathy

KW - classical pathway

KW - complement

KW - dense-deposit disease

KW - glomerulonephritis

UR - http://www.scopus.com/inward/record.url?scp=84961585340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961585340&partnerID=8YFLogxK

U2 - 10.1016/j.kint.2015.12.003

DO - 10.1016/j.kint.2015.12.003

M3 - Article

VL - 89

SP - 278

EP - 288

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 2

ER -